Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques
Exploration of Endocrine and Metabolic Diseases · 2025
DOI: 10.37349/eemd.2025.101425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, 2025. Verfasst von Pirangi Srikanth und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as a global health crisis, affecting over 30% of the population and demanding urgent attention. This redefined condition, previously known as non-alcoholic fatty liver disease (NAFLD), reflects a deeper understanding of the intricate interplay between metabolic dysfunction and liver health. At the heart of MASLD lies the troubling accumulation of triglycerides (TGs) in hepatocytes, which precipitates insulin resistance and oxidative stress, ultimately leading to more severe forms like metabolic dysfunction-associated steatohepatitis (MASH). Excitingly, recent research has spotlighted the farnesoid X receptor (FXR) as a groundbreaking therapeutic target. FXR not only regulates lipid metabolism but also combats inflammation and insulin resistance, making it a potential game-changer in the fight against MASLD. With only one FDA-approved drug, resmetirom, currently available, the exploration of FXR agonists opens new avenues for innovative treatments that could revolutionize patient care. By harnessing the power of FXR to restore metabolic balance and integrating advanced strategies like lipidomics and fatty acid profiling, we stand on the brink of transforming how we approach MASLD and its associated complications, paving the way for a healthier future. This review delves into the promising role of FXR in combating MASLD and its implications for related metabolic disorders, emphasizing the urgency for advanced strategies to detect and manage this burgeoning epidemic.
Zitieren
APA
Srikanth, P., Shaik, K. M., Patibandla, V., Kumar, D., & Nandi, S. (2025). Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques. Exploration of Endocrine and Metabolic Diseases. https://doi.org/10.37349/eemd.2025.101425
Vancouver
Srikanth P, Shaik KM, Patibandla V, Kumar D, Nandi S. Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques. Exploration of Endocrine and Metabolic Diseases. 2025. doi:10.37349/eemd.2025.101425
BibTeX
@article{Srikanth2025,
author = {Srikanth, Pirangi and Shaik, Khaja Moinuddin and Patibandla, Vijay and Kumar, Deepak and Nandi, Sukhendu},
title = {Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques},
journal = {Exploration of Endocrine and Metabolic Diseases},
year = {2025},
doi = {10.37349/eemd.2025.101425}
}
EUVIMED